Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
暂无分享,去创建一个
Mithat Gonen | Steven M Larson | S. Larson | M. Gonen | H. Strauss | R. Tuttle | R. Reibke | R. Robbins | R. Grewal | R Michael Tuttle | R. Tuttle | H William Strauss | Ravinder K Grewal | Richard J Robbins | Qiang Wan | Roland Reibke | William Drucker | W. Drucker | Qiang Wan | H. Strauss
[1] H. Katoh,et al. Evaluation of 18F-2-deoxy-2-fluoro-d-glucose Positron Emission Tomography for Gastric Cancer , 2004, World Journal of Surgery.
[2] S. Larson,et al. Positron emission tomography in thyroid cancer management. , 2002, Seminars in roentgenology.
[3] P. Ladenson,et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. , 1998, Cancer.
[4] D. Hwang,et al. Prediction of Pathology and Survival by FDG PET in Gliomas , 2003, Journal of Neuro-Oncology.
[5] J. Shah,et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. , 2003, Journal of the American College of Surgeons.
[6] J. Hanke,et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] H. Biersack,et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer , 1996, European Journal of Nuclear Medicine.
[8] E. Bergstralh,et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. , 1988, The Journal of clinical endocrinology and metabolism.
[9] B. Caillou,et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. , 1986, The Journal of clinical endocrinology and metabolism.
[10] S. Larson,et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] J. Shah,et al. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. , 1995, Surgery.
[12] T. Taguchi,et al. Preoperative evaluation of prognosis in breast cancer patients by [18F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography , 2004, Journal of Cancer Research and Clinical Oncology.
[13] S. Larson,et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[14] S. Raman,et al. Whole-body PET/CT: Spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients , 2005, Nuclear medicine communications.
[15] E. Bergstralh,et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.
[16] K. Ain. Papillary thyroid carcinoma : etiology, assessment and therapy , 1995 .
[17] Deborah Schrag,et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.
[18] K. Kaczirek,et al. Importance of tumour size in papillary and follicular thyroid cancer , 2005, The British journal of surgery.
[19] B Jennett,et al. Predicting the Outcome , 1987, Journal of the Royal Society of Medicine.
[20] M. Schlumberger,et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] S. Larson,et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.
[22] J. Høie,et al. Distant metastases in papillary thyroid cancer. A review of 91 patients , 1988, Cancer.
[23] S. Larson,et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. , 2001, Thyroid : official journal of the American Thyroid Association.
[24] J. Hanke,et al. [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. , 1995, Nuklearmedizin. Nuclear medicine.
[25] V. Lowe,et al. 18F-FDG PET of patients with Hürthle cell carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] B. Cady,et al. An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.
[27] S. Larson,et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? , 2002, The Journal of clinical endocrinology and metabolism.
[28] N. Sadato,et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[29] P. Ladenson,et al. Prospective multicenter study of thyroid carcinoma treatment , 1998 .
[30] N. Samaan,et al. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. , 1983, The Journal of clinical endocrinology and metabolism.
[31] S. Dinneen,et al. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. , 1995, The Journal of clinical endocrinology and metabolism.
[32] R. Wahl,et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.